Eric Schmidt
2019
In 2019, Eric Schmidt earned a total compensation of $3.5M as Chief Financial Officer at Allogene Therapeutics, a 34% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $187,000 |
|---|---|
| Option Awards | $1,519,700 |
| Salary | $425,000 |
| Stock Awards | $1,328,366 |
| Total | $3,460,066 |
Schmidt received $1.5M in option awards, accounting for 44% of the total pay in 2019.
Schmidt also received $187K in non-equity incentive plan, $425K in salary and $1.3M in stock awards.
Rankings
In 2019, Eric Schmidt's compensation ranked 3,525th out of 13,971 executives tracked by ExecPay. In other words, Schmidt earned more than 74.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,525 out of 13,971 | 75th |
Division Manufacturing | 1,276 out of 5,695 | 78th |
Major group Chemicals And Allied Products | 441 out of 2,194 | 80th |
Industry group Drugs | 368 out of 1,880 | 80th |
Industry Biological Products, Except Diagnostic Substances | 80 out of 389 | 79th |
Source: SEC filing on April 23, 2020.
Schmidt's colleagues
We found three more compensation records of executives who worked with Eric Schmidt at Allogene Therapeutics in 2019.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019